A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Clinical trial NCT02336451 · COMPLETED
Trial details
- NCT number
- NCT02336451
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-01
- Primary completion
- 2019-02-06
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.